Naveen Garg

Family Medicine
99 Woodland St
Hartford, CT 06105

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Journal: Blood cancer discovery
Published: October 18, 2025

AI solutions to the radiology workforce shortage.

AI solutions to the radiology workforce shortage.

Journal: npj health systems
Published: February 26, 2025

Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.

Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.

Journal: PloS one
Published: December 07, 2023

Automated Spontaneous Echo Contrast Detection Using a Multisequence Attention Convolutional Neural Network.

Automated Spontaneous Echo Contrast Detection Using a Multisequence Attention Convolutional Neural Network.

Journal: Ultrasound in medicine & biology
Published: October 03, 2023

Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial.

Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial.

Journal: Annals of surgery
Published: April 07, 2023

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.

Journal: Leukemia
Published: December 25, 2022

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.

Journal: Blood advances
Published: August 23, 2022

A phase two study of high dose blinatumomab in Richter's syndrome.

A phase two study of high dose blinatumomab in Richter's syndrome.

Journal: Leukemia
Published: May 19, 2022

Association of Flame-Retardant Clothing With Mycosis Fungoides: A Retrospective Analysis.

Association of Flame-Retardant Clothing With Mycosis Fungoides: A Retrospective Analysis.

Journal: Dermatology practical & conceptual
Published: October 21, 2021

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer.

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer.

Journal: Journal of gastrointestinal oncology
Published: August 04, 2021

Correction to: Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer.

Correction to: Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer.

Journal: Thrombosis journal
Published: July 15, 2021

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Journal: JAMA oncology
Published: June 10, 2021
Showing 1-12 of 71

Last Updated: 09/26/2026